Riskpilot← Back to searchSign inGet full accessUppsala Biotech AB
ABActiveOrg 5569389405Vårdkasvägen 7Engineering activities and related technical consultancy · NACE 7112Est. 20130 employees
Revenue 2025
SEK 1,2M
+12% vs 2024
EBITDA margin
12.4%
-80% vs 2024
Equity ratio
96.5%
Financial strength
Net profit 2025
SEK -18K
-103% vs 2024
| Revenue | SEK 1,2M | +12% |
| EBITDA | SEK 146K | -80% |
| Net profit | SEK -18K | -103% |
| Total assets | SEK 4,3M | -35% |
| Equity | SEK 4,2M | -5% |
| Employees | 0 | — |
Legal name
Uppsala Biotech AB
Org number
5569389405
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
12 augusti 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva konsultverksamhet inom bioteknologi. Bolaget ska vidare äga och utveckla patent och andra rättigheter inom bioteknik, äga fast och lös egendom samt bedriva därmed förenlig verksamhet. Hyra ut mig själv som sjökapten.
Address
Vårdkasvägen 7
Email
hans.johansson@purolite.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 969 | 2 162 | 2 381 | 1 055 | 1 182 |
| Staff expenses | — | — | −263 | −48 | −788 |
| EBITDA | 1 088 | 959 | 1 865 | 737 | 146 |
| Depreciation & amort. | −7 | −12 | −9 | −9 | −9 |
| EBIT | 1 081 | 947 | 1 857 | 729 | 119 |
| Net financials | 3 | 11 | −1 616 | 128 | −117 |
| Profit before tax | 1 182 | 1 110 | 340 | 857 | 4 |
| Tax | −245 | −230 | −352 | −173 | −22 |
| Net profit | 937 | 880 | −12 | 684 | −18 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 367 | 6 654 | 6 324 | 6 691 | 4 326 |
| Equity | 3 635 | 4 241 | 3 921 | 4 400 | 4 173 |
| Long-term debt | 2 314 | 2 313 | 2 307 | 2 290 | 0 |
| Short-term debt | 166 | 0 | 95 | 0 | 153 |
| Total debt | 2 480 | 2 313 | 2 403 | 2 290 | 153 |
EBITDA margin
12.4%
This company
15.8%
Market median
-22% vs market
20212025
Equity ratio
96.5%
This company
38.2%
Market median
+153% vs market
20212025
Return on equity
-0.4%
This company
18.4%
Market median
-102% vs market
20212025
Net profit margin
-1.5%
This company
8.1%
Market median
-119% vs market
20212025
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Uppsala Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Monika Elisabeth Johansson | Deputy Board Member | 0 companies |
| Hans Olle Joel Johansson | Board of Directors | 0 companies |